Historical mrna News Stories
Moderna Shorted Heavily; $140M Backs Norwood Build
Recent reporting shows Moderna has become one of the most heavily shorted large-cap names while simultaneously committing $140 million to complete a domestic mRNA manufacturing site in Norwood. This article explains the short-interest dynamics, the strategic manufacturing investment, and how these developments affect MRNA stock.
Moderna Boosts Liquidity; Q3 Revenue Pressures Q4!
Moderna secured a $1.5B non-dilutive credit facility, committed $140M to complete U.S. mRNA manufacturing, and reported a Q3 revenue decline with narrowed full-year guidance. These concrete actions strengthen liquidity and operational control but leave near-term revenue and profitability challenges that investors should weigh against upcoming clinical and commercial catalysts.
Moderna Hits Turbulence: Q3 Results, CMV Cut, Vote
Moderna's recent week brought a mixed signal: a Q3 revenue beat but narrower guidance, termination of the CMV program, and a shareholder vote on an option exchange that could reduce dilution. Analysts remain cautious while institutional moves show both trimming and new interest.
Moderna Gains FDA Nod; US Cancels $766M Flu Deal!!
Moderna won FDA approval for its next‑generation COVID vaccine mNEXSPIKE while the U.S. government simultaneously cancelled roughly $766M in bird‑flu vaccine contracts — a one‑two punch that produced mixed signals for MRNA stock, combining immediate commercial upside with a loss of government funding and political headwinds.